Gefitinib, as one of the anticancer therapeutics directed against EGFR, can inhibit tumor growth.41 Here, we found that gefitinib treatment inhibited tumor metastasis and decreased TGIF2 phosphorylation in vitro and in vivo. Here, TGIF2 is linked to neoplasm.